CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates.

  title={CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates.},
  author={Allan D. Kirk and David M Harlan and Normadeane Armstrong and Thomas A. Davis and Yinchen Dong and Gary S. Gray and Xiaoman Hong and Dolca Thomas and John J H Fechner and Stuart J Knechtle},
  journal={Proceedings of the National Academy of Sciences of the United States of America},
  volume={94 16},
Selective inhibition of T cell costimulation using the B7-specific fusion protein CTLA4-Ig has been shown to induce long-term allograft survival in rodents. Antibodies preventing the interaction between CD40 and its T cell-based ligand CD154 (CD40L) have been shown in rodents to act synergistically with CTLA4-Ig. It has thus been hypothesized that these agents might be capable of inducing long-term acceptance of allografted tissues in primates. To test this hypothesis in a relevant preclinical… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 248 extracted citations

Current and Future Immunosuppressive Therapies Following Transplantation

Mohamed H. Sayegh, Giuseppe Remuzzi, +7 authors CONTRIBUTORS LIST
Springer Netherlands • 2001
View 4 Excerpts
Highly Influenced

De novo belatacept in clinical vascularized composite allotransplantation.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons • 2018

Belatacept in kidney transplantation - past and future perspectives.

Jornal brasileiro de nefrologia : 'orgao oficial de Sociedades Brasileira e Latino-Americana de Nefrologia • 2017


Publications referenced by this paper.

Kirk et al

Z. W. Chen, S. N. McAdam, +5 authors 2547–2554. 8794 Medical Sciences
Proc. Natl. Acad. Sci. USA 94 • 1997

Similar Papers

Loading similar papers…